The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Type 2 diabetes mellitus (T2DM) is a prevalent yet complex metabolic disorder that has shown a rising incidence over the past few decades. Recent research has identified flavonoids as compounds ...

The use of an automated insulin delivery (AID) system reduced A1c and hyperglycemia without increasing hypoglycemia in people ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

HealthDay News — For patients with type 2 diabetes (T2D), glucagon-like peptide-1 receptor ... developing hematologic cancers compared with insulin and metformin use, according to a research ...

SFC Fluidics, Inc. ("SFC") and Duracell U.S. Operations, Inc. ("Duracell") are collaborating to efficiently deliver power to SFC's dual-hormone insulin and glucagon delivery pod. The goal of this ...

Lilly launches Mounjaro in India, offering new option to treat obesity and type 2 diabetes: Our Bureau, Bengaluru Thursday, ...